New treatment options are being studied and proposed but much work is required to understand how these technologies are best matched with specific patients and pain syndromes.
A recent article delves into the details of this topic. The article concludes with a statement that "the field will undoubtedly continue to grow and force reconsideration of current treatment paradigms.".
This implies that new research on new paradigms require new devices. Flexible, programmable, indication-agnostic devices can play a key role in accelerating medical research, given the fact that developing a new purpose-built device requires a dedicated development team and heavy investment in time, and money.
A programmable device can enable new research overnight.
Lone Star NeuroMODULATION
LSN is targeting unmet clinical needs by creating disruptive device platforms that offer promising solutions for lowering costs, realizing higher returns and effectively addressing more therapeutic indications if adopted for medical applications.